SCHEMBL224606

SCHEMBL224606

O=C1[N]C=Cc2ccccc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
IDO1 P14902 3/20 0.45
POLB P06746 3/20 0.45
KDM4E B2RXH2 2/20 0.45
LMNA P02545 2/20 0.45
BCHE P06276 2/20 0.45
PTPRC P08575 2/20 0.45
MAPT P10636 2/20 0.45
THRB P10828 2/20 0.45
CES1 P23141 2/20 0.45
RECQL P46063 2/20 0.45
ALOX15 P16050 2/20 0.45
ALDH1A1 P00352 2/20 0.45
PKM P14618 1/20 0.45
HPGD P15428 1/20 0.45
PTPN1 P18031 1/20 0.45
ACHE P22303 1/20 0.45
HSD17B10 Q99714 1/20 0.45
PTPN22 Q9Y2R2 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1245585 0.73 KDM4E (0.35) MEN1KMT2AIDO1POLBKDM4E
SCHEMBL9201732 0.73 KDM4E (0.35) MEN1KMT2AIDO1POLBKDM4E
SCHEMBL3358801 0.72 MAOA (0.39) KDM4EMAPTCDC25BMAOAMAOB
SCHEMBL1096641 0.68 MAOA (0.36) MEN1KMT2APOLBKDM4ELMNA
SCHEMBL113314 0.67 GSK3B (0.40) MEN1KMT2AIDO1POLBKDM4E
SCHEMBL29394879 0.67 GSK3B (0.40) MEN1KMT2AIDO1POLBKDM4E
SCHEMBL25894 0.65
SCHEMBL29409540 0.65 MEN1 (0.73) MEN1KMT2AIDO1POLBKDM4E
SCHEMBL2627989 0.65 MEN1 (0.73) MEN1KMT2AIDO1POLBKDM4E
SCHEMBL16710160 0.65 MEN1 (0.38) MEN1KMT2AIDO1POLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 979 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220298174-A1 TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD (CN) 2022-09-22 US claimed
EP-4011886-A1 TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) 2022-06-15 EP claimed
EP-4006016-A2 PROBES FOR IMAGING HUNTINGTIN PROTEIN CHDI Foundation, Inc. (US) 2022-06-01 EP claimed
CN-112300195-B Tetra-fused ring compound and preparation method and application thereof 上海济煜医药科技有限公司 2021-12-24 CN claimed
US-20210198235-A1 DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF AURANSA INC. 2021-07-01 US claimed
WO-2021052499-A1 FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海济煜医药科技有限公司 2021-03-25 WO claimed
CN-112300195-A Tetra-fused ring compound and preparation method and application thereof 上海济煜医药科技有限公司 2021-02-02 CN claimed
US-20200031799-A1 THERAPEUTIC INHIBITORY COMPOUNDS ATTUNE PHARMACEUTICALS, INC. 2020-01-30 US claimed
US-20200031800-A1 THERAPEUTIC INHIBITORY COMPOUNDS ATTUNE PHARMACEUTICALS, INC. 2020-01-30 US claimed
US-20190263783-A1 THERAPEUTIC INHIBITORY COMPOUNDS ATTUNE PHARMACEUTICALS, INC. 2019-08-29 US claimed
EP-0794953-B1 QUINAZOLINE DERIVATIVES ZENECA LTD (GB) 1999-05-06 EP claimed
EP-0584222-A4 BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE RHONE POULENC RORER INT (US) 1994-07-06 EP claimed
EP-0584222-A1 BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE. RHONE POULENC RORER INT (US) 1994-03-02 EP claimed
EP-0561357-A1 Pharmaceutical composition comprising a potassium-channel-opener and an antagonist of angiotensin-II receptors MERCK PATENT GmbH (DE) 1993-09-22 EP claimed
WO-1992020642-A1 BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) 1992-11-26 WO claimed
US-5114952-A Side effect reduction PFIZER INC. (US) 1992-05-19 US claimed
EP-0401505-A2 Pharmaceutical composition containing a potassium channel-activator and an ace-inhibitor MERCK PATENT GmbH (DE) 1990-12-12 EP claimed
EP-0346724-A1 Chroman derivates MERCK PATENT GmbH (DE) 1989-12-20 EP claimed
EP-0067094-B1 HETEROCYCLIC DERIVATIVES OF AMIDOXIMES, THEIR PREPARATION AND THERAPEUTIC USES SYNTHELABO (FR) 1985-10-02 EP claimed
US-4438121-A CENTRAL NERVOUS SYSTEM DISORDER TREATMENT, ANTIDEPRESSANTS SYNTHELABO (FR) 1984-03-20 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200031800-A1 THERAPEUTIC INHIBITORY COMPOUNDS KLKB1, SERPINB1, SERPINE1 MEN1 1423/4885KMT2A 1049/4885IDO1 1136/4885
US-20200031799-A1 THERAPEUTIC INHIBITORY COMPOUNDS KLKB1, SERPINB1, SERPINE1 MEN1 1423/4885KMT2A 1049/4885IDO1 1136/4885
US-20190263783-A1 THERAPEUTIC INHIBITORY COMPOUNDS SERPINB1, KLKB1, SERPINE1 MEN1 2086/4885KMT2A 1381/4885IDO1 1036/4885
US-20220298174-A1 TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF KRAS, NRAS, HRAS MEN1 204/4885KMT2A 3656/4885IDO1 4705/4885
US-20210198235-A1 DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF THPO, PIR, PAK6 MEN1 1394/4885KMT2A 2507/4885IDO1 1611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.